Clinical trials: HFpEF - Heart Failure With Preserved Ejection Fraction
Heart Failure, Diastolic
Respiratory Muscle Function in Heart Failure
This study is being done because investigators are trying to determine how respiratory muscle and lung function influence the exercise responses in heart failure and healthy participants.
- Trial name
- NCT03924479
- Testing
- PowerBreathe (Breathing muscle training)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Heart Failure
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
The purpose of this study is to evaluate the safety, tolerability, and exposure-response (E-R) of BMS-986435/MYK-224 in participants with symptomatic Heart Failure with Preserved Ejection Fraction (HFpEF).
- Trial name
- AURORA-HFpEF (NCT06122779)
- Testing
- BMS-986435
- Where
- 86 sites in United States, Argentina and 9 more
- Volunteers
- 227 people
- Sponsor
- Bristol-Myers Squibb
Heart Failure With Preserved Ejection Fraction
Cardiac Magnetic Resonance Assessment for Heart Failure With Preserved Ejection Fraction
This is a prospective study that aims to define the utility of cardiac magnetic resonance feature tracking (CMR-FT) as a non-invasive quantification tool to assess diastolic functionality in patients with Heart Failure with…
- Trial name
- NCT04063579
- Testing
- Cardiac Magnetic Resonance, Echocardiogram, Blood investigation (NT-proBNP), cardiac catheterization, Cardiac Magnetic Resonance, Echocardiogram, Blood investigation (NT-proBNP)
- Where
- Hong Kong
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
Heart Failure, Diastolic
Value of Intense Phenotyping in Heart Failure With Preserved Ejection Fraction
Heart failure (HF) with a left ventricular ejection fraction (LVEF) >0.40 is a large medical problem, for which no drug or device has a recommendation in current HF guidelines.
- Trial name
- VIP-HF2 (NCT05479669)
- Testing
- Echocardiography, 24 hour Holter monitoring, Cardiac Magnetic Resonance Imaging
- Where
- Netherlands
- Volunteers
- 200 people
- Sponsor
- University Medical Center Groningen
Heart Failure With Preserved Ejection Fraction
Chemoreflex Sensitivity in HFpEF
Patients with heart failure and a preserved left ventricular ejection fraction (HFpEF) almost invariably complain of exertional breathlessness.
- Trial name
- CHEMO-HFpEF (NCT06309537)
- Testing
- chemoreflex evaluation
- Where
- Italy
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Istituto Auxologico Italiano
Healthy Volunteers
A Study to Assess the Relative Bioavailability and Safety of Different Formulations of AZD4831 in Fasted State in Healthy Volunteers.
A study to assess the relative bioavailability and safety of different formulations of AZD4831 in fasted state in healthy volunteers.
- Trial name
- NCT05457270
- Testing
- AZD4831
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Heart Failure With Preserved Ejection Fraction
Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%
This is a randomised, double-blind, placebo-controlled, multi-center sequential phase 2b and Phase 3 study to evaluate the efficacy and safety of AZD4831 administered for up to 48 Weeks in participants with heart failure with…
- Trial name
- ENDEAVOR (NCT04986202)
- Testing
- AZD4831
- Where
- 171 sites in United States, Australia and 16 more
- Volunteers
- 711 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2, HFpEF - Heart Failure With Preserved Ejection Fraction
Emulation of the STEP-HFpEF DM Heart Failure Trial in Healthcare Claims Data
Investigators are building an empirical evidence base for real-world data through large-scale emulation of randomized controlled trials.
- Trial name
- DUP-STEP-HFpEF (NCT06914102)
- Testing
- Semaglutide
- Where
- United States
- Volunteers
- 58,387 people
- Sponsor
- Brigham and Women's Hospital
Dyspnea
Diagnosing Heart Failure With Preserved Ejection Fraction in Patients With Unexplained Dyspnea (Diagnose-HFpEF)
Invasive diagnosis of heart failure with preserved ejection fraction (HFpEF) in patients with unexplained dyspnea NYHA II-III compared to other diagnostic tools
- Trial name
- NCT04688905
- Testing
- Invasive hemodynamics of left ventricle via conductance catheter at rest, with exercise and with temporary vena cava occlusion
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- University of Leipzig
Heart Failure With Normal Ejection Fraction
Cell Therapy in HFpEF
The primary objective of the study is to investigate safety and efficacy of transendocardial CD34+ cell therapy in patients with HFpEF by evaluating changes in myocardial structure and function, patient exercise capacity and…
- Trial name
- CELLpEF (NCT02923609)
- Testing
- Cell Therapy
- Where
- Slovenia
- Volunteers
- 30 people
- Sponsor
- University Medical Centre Ljubljana
Heart Failure, Diastolic, Heart Failure, Systolic
Network Medicine Approaches to Classify Heart Failure With PReserved Ejection Fraction by Signatures of DNA Methylation and Point-of-carE Risk calculaTors (PRESMET)
Heart failure (HF) is a syndrome, resulting from structural or functional impairment of ventricular filling or ejection of blood.
- Conditions
- Heart Failure, Diastolic, Heart Failure, Systolic, Pulmonary Hypertension, Atrial Fibrillation
- Trial name
- PRESMET (NCT05475028)
- Testing
- RRBS
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- University of Campania Luigi Vanvitelli
Heart Failure, Inflammation
Colchicine in HFpEF
Heart failure is a growing epidemic that affects up to 500,000 individuals in Canada, with 50,000 new cases being diagnosed each year. Half of these will have HF with preserved ejection fraction (HFpEF).
- Conditions
- Heart Failure, Inflammation, Colchicine
- Trial name
- COLpEF (NCT04857931)
- Testing
- Colchicine
- Where
- Canada
- Volunteers
- 14 people
- Sponsor
- Montreal Heart Institute
Heart Failure, Acute Heart Failure
Pharmacological Optimization in Prevention in Heart Failure: A Sex-gap?
The goal of this clinical trial is to learn whether a rapid and intensive optimization of heart failure medications in women can improve outcomes after hospitalization for heart failure.
- Conditions
- Heart Failure, Acute Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF), Heart Failure With Preserved Ejection Fraction (HFPEF)
- Trial name
- PopS-HF (NCT07295522)
- Testing
- Guideline-Directed Medical Therapy (GDMT)
- Where
- 12 sites in Italy
- Volunteers
- 368 people
- Sponsor
- IRCCS Policlinico S. Donato
Congestive Heart Failure (CHF)
Evaluation of the Use of Empagliflozin in Patients with HF with PEF in a Cardiology Outpatient Department
This study aims to evaluate whether the use of a 25 mg dose of empagliflozin compared to the 10 mg dose used would bring additional benefits in the improvement outcomes of the Kansas City Cardiomyopathy Questionnaire (KCCQ SST)…
- Trial name
- ADDEMFEP (NCT06683053)
- Testing
- empagliflozin
- Where
- Brazil
- Volunteers
- 90 people
- Sponsor
- Conrado Roberto Hoffmann Filho
Heart Failure With Preserved Ejection Fraction
Dapagliflozin (DAPA) Effects in HFpEF
The purpose of this study is to determine whether treatment with Dapagliflozin (DAPA) for 6 months will improve pulmonary capillary wedge pressure (PCWP) during exercise in heart failure/preserved ejection fraction (HFpEF) and…
- Trial name
- NCT04730947
- Testing
- Dapagliflozin
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Mayo Clinic
Heart Failure With Preserved Ejection Fraction (HFPEF)
Mangafodipir - an Intracellular Contrast Agent for Magnetic Resonance Imaging (MRI): Measuring Manganese Uptake Rate in Heart Failure Patients With Preserved Ejection Fraction (HFpEF) Patients.
More than half of heart failure patients have preserved ejection fraction (HFpEF), a condition caused by increased wall stiffness that impairs proper heart filling.
- Trial name
- NCT06731738
- Testing
- Gadoteric acid, Mangafodipir trisodium injection
- Where
- Norway
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- IC TARGETS AS
Heart Failure, Healthy Volunteer
Study to Evaluate the Safety and Tolerability of AMG 986 in Healthy Volunteers and Heart Failure Patients
To evaluate the safety and tolerability of ascending single (Part A) and ascending multiple (Part B) doses of AMG 986 in healthy adults and of ascending multiple oral doses of AMG 986 in heart failure patients (Part C).
- Trial name
- NCT03276728
- Testing
- AMG 986 IV, AMG 986 PO
- Where
- 25 sites in United States, Australia and 7 more
- Volunteers
- 182 people, healthy volunteers welcome
- Sponsor
- Amgen
Heart Failure, HFpEF
Deprescribing Beta-Blockers in Elders With Heart Failure With Preserved Ejection Fraction (DEPRESCRIBE-HFpEF)
The goal of this study is to learn whether stopping beta-blockers can help older adults with heart failure with preserved ejection fraction (HFpEF) feel better and function better.
- Conditions
- Heart Failure, HFpEF, HFpEF - Heart Failure With Preserved Ejection Fraction
- Trial name
- DEPRESCRIBE (NCT07298993)
- Testing
- Beta-blockers
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- Weill Medical College of Cornell University
Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
Administration of the SGLT-2 Inhibitor Dapagliflozin in the Patients With Amyloid Cardiomyopathy
Efficacy and safety of early administration of the SGLT-2 inhibitor dapagliflozin will be evaluated in patients with HF, regardless of LVEF, due to amyloid cardiomyopathy.
- Conditions
- Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Amyloid Cardiomyopathy
- Trial name
- NCT05795400
- Testing
- Dapagliflozin 10mg Tab
- Where
- Russia
- Volunteers
- 50 people
- Sponsor
- National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Transthyretin Amyloid Cardiomyopathy, Heart Failure With Preserved Ejection Fraction
Global Prevalence of ATTR-CM in Participants With HFpEF
This study is a global, multi-center study designed to estimate the global prevalence of transthyretin amyloid cardiomyopathy (ATTR-CM) within a clinically at risk population [participants with heart failure with preserved…
- Trial name
- NCT04424914
- Testing
- Scintigraphy
- Where
- 51 sites in United States, Canada and 6 more
- Volunteers
- 347 people
- Sponsor
- Pfizer